Company profile
VOR BIOPHARMA INC.
NASDAQ:VORBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TELITACICEPT | phase3 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06456580 | phase3 | recruiting | 2024-07-17 | 2027-05-01 | Vor Biopharma | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) |
| NCT05306574 | phase3 | terminated | 2022-06-20 | 2025-01-06 | Vor Biopharma | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) |
| NCT06456567 | phase3 | withdrawn | 2024-09-01 | 2025-01-02 | Vor Biopharma | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) |
| NCT04849910 | phase1_2 | terminated | 2021-12-16 | 2025-05-28 | Vor Biopharma | Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS |
| NCT05984199 | phase1_2 | terminated | 2023-12-11 | 2025-05-28 | Vor Biopharma | Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant |
FDA applications (0)
No records yet.